Ingenol mebutate: From common weed to cancer cure

Current Problems in Dermatology (Switzerland)

Volumn 46, Issue , 2015, Pages 136-142

  Zarchi, Kian ^a   Jemec, Gregor B E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE; 3-INGENYL ANGELATE; ANTINEOPLASTIC AGENT; DITERPENE; PLANT EXTRACT; PROTEIN KINASE INHIBITOR;

ACTINIC KERATOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FOLLOW UP; GEL; HUMAN; INFLAMMATION; NONHUMAN; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEED; KERATOSIS, ACTINIC; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; DITERPENES; HUMANS; KERATOSIS, ACTINIC; PLANT EXTRACTS; PROTEIN KINASE INHIBITORS;

EID: 84929471290     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000366549     Document Type: Article

References (29)

1. Lebwohl M: Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol 2003; 149(suppl 66):31-33.
2. Salasche SJ: Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:4-7.
3. Heaphy MR Jr, Ackerman AB: The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000; 43:138-150.
4. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, Sterry W, Stockfleth E: Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(suppl 3):8-12.
5. Ackerman AB, Mones JM: Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155:9-22.
6. Moy RL: Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:8-10.
7. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G: Management of field change in actinic keratosis. Br J Derma-tol 2007; 157(suppl 2):21-24.
8. Nambudiri NS, Nambudiri VE: Euphorbia peplus: 18th-century insights on a 21st-century therapy. JAMA Dermatol 2013; 149:1081.
9. Rosen RH, Gupta AK, Tyring SK: Dual mechanism of action of ingenol mebu-tate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012; 66:486-493.
10. Weedon D, Chicj J: Home treatment of basal cell carcinoma. Med J Aust 1976; 1: 928.
11. Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, McAlp-ine D, Johns J, Scott TM, Sutherland KP, Gardner JM, Le TT, Lenarczyk A, Ayl-ward JH, Parsons PG: Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and ne-crotic cell death. Cancer Res 2004; 64: 2833-2839.
12. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, Le TT, Hoang-Le D, Ogbourne SM: Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006; 177:8123-8132.
13. Cozzi SJ, Ogbourne SM, James C, Rebel HG, de Gruijl FR, Ferguson B, Gardner J, Lee TT, Larcher T, Suhrbier A: Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 2012; 132:1263-1271.
14. Gillespie SK, Zhang XD, Hersey P: In-genol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther 2004; 3:1651-1658.
15. Cozzi SJ, Parsons PG, Ogbourne SM, Pedley J, Boyle GM: Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-depen-dent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 2006; 66:10083-10091.
16. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, Bunce CM, Lord JM: PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005; 106:1362-1368.
17. Benhadji KA, Serova M, Ghoul A, Cvit-kovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E: Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer 2008; 99:1808-1815.
18. Le TT, Gardner J, Hoang-Le D, Schmidt CW, MacDonald KP, Lambley E, Schroder WA, Ogbourne SM, Suhrbier A: Im-munostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine 2009; 27:3053-3062.
19. Lee WY, Hampson P, Coulthard L, Ali F, Salmon M, Lord JM, Scheel-Toellner D: Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. J Biol Chem 2010; 285:23889-23898.
20. Ersvaer E, Hampson P, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø: Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology 2007; 12:199-207.
21. Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed Rainger G: The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother 2008; 57:1241-1251.
22. Li L, Shukla S, Lee A, Garfield SH, Malo-ney DJ, Ambudkar SV, Yuspa SH: The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 2010; 70:4509-4519.
23. Siller G, Gebauer K, Welburn P, Kat-samas J, Ogbourne SM: PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009; 50:16-22.
24. Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, Katsamas J: Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025 and 0.05% for actinic keratosis. J Am Acad Dermatol 2009; 60:934-943.
25. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B: Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366:1010-1019.
26. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK: Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149: 666-670.
27. Miller IM, Nielsen JS, Lophaven S, Jem-ec GB: Factors related to pain during routine photodynamic therapy: a descriptive study of 301 patients. J Eur Acad Dermatol Venereol 2011; 25:1275-1281.
28. Gupta AK, Paquet M, Villanueva E, Brintnell W: Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12:CD004415.
29. Gupta AK, Paquet M: Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosup-pressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169:250-259.